SS-31: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข3 community protocols documented
- โขEvidence level: Anecdotal Reports
- โขBased on 30 community reports
- โข2 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Administration Route | Clinical trials primarily use intravenous infusion (0.01-0.25 mg/kg/h) or subcutaneous injection (40 mg daily in the Barth syndrome TAZPOWER trial). Some studies use single-dose IV infusion protocols. | Community exclusively uses subcutaneous injection at much lower doses (1-5 mg) than clinical trial SubQ dosing (40 mg). IV infusion is impractical for self-administration. | moderate While SubQ is used in some clinical trials, community doses are significantly lower than the 40 mg/day used in the TAZPOWER trial. The pharmacologically effective SubQ dose for anti-aging indications in humans is unknown. |
| Indication | Elamipretide (FORZINITY) received FDA accelerated approval in September 2025 for Barth syndrome. Clinical development also targeted primary mitochondrial myopathy, heart failure, and renal ischemia-reperfusion injury. These are specific mitochondrial and cardiovascular diseases. | Community uses SS-31 for general anti-aging, exercise performance, and mitochondrial optimization in healthy individuals. These applications are extrapolated from the disease-specific clinical data. | high Treating mitochondrial disease in patients with genetic defects is fundamentally different from enhancing mitochondrial function in healthy individuals. Clinical efficacy in disease states does not necessarily predict benefits for healthy users. |
| Dosing | Clinical SubQ dose in Barth syndrome is 40 mg daily. IV infusion doses range from 0.01 to 0.25 mg/kg/h. Mouse anti-aging studies used 3 mg/kg/day SubQ for 8 weeks. | Community doses of 1-5 mg SubQ are significantly lower than clinical SubQ dosing (40 mg) but closer to HED estimates from the 3 mg/kg mouse dose (approximately 0.24 mg/kg, or 17 mg for a 70 kg person). | moderate Community doses are lower than both clinical and properly scaled mouse doses. Whether these doses achieve meaningful mitochondrial membrane concentrations is unknown. |
Compare these community approaches with published research findings.
Community Protocols
Standard SubQ Anti-Aging Protocol
Common- Route
- Subcutaneous
- Dose
- 1-5 mg
- Frequency
- Once daily
- Duration
- 4-8 weeks
Most commonly discussed community protocol; dose range adapted from clinical trial data with allometric scaling
Low-Dose Maintenance Protocol
Niche- Route
- Subcutaneous
- Dose
- 0.5-1 mg
- Frequency
- 3-5 times per week
- Duration
- 8-12 weeks with breaks
Lower frequency protocol for long-term mitochondrial support; less aggressive than daily dosing
Exercise Performance Protocol
Niche- Route
- Subcutaneous
- Dose
- 2-5 mg
- Frequency
- Once daily or pre-exercise
- Duration
- 4-8 weeks
Timed around exercise for potential mitochondrial performance enhancement; inspired by mouse exercise studies
Stacking Patterns
SS-31 + MOTS-c Mitochondrial Stack
NicheDual mitochondrial peptide approach targeting inner membrane (SS-31 cardiolipin stabilization) and AMPK activation (MOTS-c) for comprehensive mitochondrial support
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 30+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|SS-31/Elamipretide experience reports and dosing discussions(accessed 2026-02-16)
- Reddit r/Nootropics|SS-31 mitochondrial peptide discussions(accessed 2026-02-16)
- Innerbody|SS-31 Peptide benefits, safety and buying advice(accessed 2026-02-16)
- Peptide Initiative|SS-31 Dosing Protocol clinical guidelines(accessed 2026-02-16)
- International Peptide Society|SS-31 monograph and clinical overview(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for SS-31 (Elamipretide). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
SS-31 has generated significant community interest as a mitochondria-targeted peptide with compelling preclinical anti-aging data. Mouse studies showing reversal of age-related mitochondrial dysfunction and improved exercise tolerance have driven community adoption, despite the fact that clinical development targets specific mitochondrial diseases rather than general anti-aging.
Understanding Protocol Divergence#
Disease vs. Anti-Aging Use#
SS-31 (Elamipretide) received FDA accelerated approval in September 2025 as FORZINITY for Barth syndrome, and clinical development also targeted primary mitochondrial myopathy and cardiovascular conditions (heart failure). Community use targets general anti-aging and mitochondrial optimization in healthy individuals. These represent fundamentally different applications with different risk-benefit considerations.
Dose Gap#
Community SubQ doses (1-5 mg) are significantly lower than clinical SubQ dosing (40 mg daily in TAZPOWER). While community doses may be closer to allometrically scaled mouse doses, the pharmacologically effective dose for anti-aging indications in humans has not been established.
Commonly Reported Outcomes#
Community reports for SS-31 include:
- Energy levels: Some users report improved subjective energy, particularly during exercise
- Recovery: Reports of improved recovery from exercise and physical stress
- Subtle effects: Many users note that effects are gradual and subtle rather than immediately noticeable
- Well-tolerated: Generally reported as well-tolerated with minimal side effects at community doses
Important Caveats#
- Clinical trials target disease states, not healthy anti-aging
- Community doses are significantly lower than clinical doses
- Subjective energy improvements are highly susceptible to placebo effect
- Long-term effects of exogenous mitochondrial peptide supplementation in healthy individuals are unknown
- Product quality is a concern for this specialized research peptide
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About SS-31
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.